Allogeneic transplantation as anticancer immunotherapy

Current Opinion in Immunology

Volumn 27, Issue 1, 2014, Pages 38-45

  Parmar, Simrit ^a   Ritchie, David S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HUMANS; IMMUNOTHERAPY; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84894093770     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.01.010     Document Type: Review

References (59)

1. Cornelissen J.J., Breems D., van Putten W.L., Gratwohl A.A., Passweg J.R., Pabst T., et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 2012, 30:2140-2146.
2. Pulsipher M.A., Wall L.B., Schultz D.A., Bunin K.R., Gastier-Foster N., Borowitz J.M., Goyal M.J., Gardner R., Carroll S., Raetz W.L., Grupp E.S.A. The relationship of acute GVHD and pre- and post-transplant flow-MRD to the incidence and timing of relapse in children undergoing allogeneic transplantation for high risk ALL: defining a target population and window for immunological intervention to prevent relapse. Blood 2012, 120. (ASH Annual Meeting Abstracts).
3. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
4. Sehn L.H., Alyea E.P., Weller E., Canning C., Lee S., Ritz J., et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 1999, 17:561-568.
5. Elmaagacli A.H., Beelen D.W., Trenn G., Schmidt O., Nahler M., Schaefer U.W. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:771-777.
6. Schmid C., Labopin M., Nagler A., Bornhauser M., Finke J., Fassas A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
7. Krishnamurthy P., Potter V.T., Barber L.D., Kulasekararaj A.G., Lim Z.Y., Pearce R.M., et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013, 19:562-568.
8. Terwey T.H., Le Duc T.M., Hemmati P.G., le Coutre P., Nagy M., Martus P., et al. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol 2013, 24:1363-1370.
9. El-Jurdi N., Reljic T., Kumar A., Pidala J., Bazarbachi A., Djulbegovic B., et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy 2013, 5:457-466.
10. Bloor A.J., Thomson K., Chowdhry N., Verfuerth S., Ings S.J., Chakraverty R., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:50-58.
11. Beitinjaneh A.M., Saliba R., Bashir Q., Shah N., Parmar S., Hosing C., et al. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma 2012, 53:1525-1529.
12. Childs R., Chernoff A., Contentin N., Bahceci E., Schrump D., Leitman S., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343:750-758.
13. de Souza J.A., Davis M.L., Rondon G., Cheng Y.C., Jones R.B., Champlin R.E., et al. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 2009, 44:81-87.
14. Eibl B., Schwaighofer H., Nachbaur D., Marth C., Gachter A., Knapp R., et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996, 88:1501-1508.
15. Pasquini M.C., Wang Z., Horowitz M.M., Gale R.P. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl 2010, 87-105.
16. Toubai T., Sun Y., Luker G., Liu J., Luker K.E., Tawara I., et al. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood 2013, 121:4231-4241.
17. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
18. Gill S., Vasey A.E., De Souza A., Baker J., Smith A.T., Kohrt H.E., et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 2012, 119(24):5758-5768.
19. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J.P., Wang T., Le C.T., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
20. Chu J., Deng Y., Benson D.M., He S., Hughes T., Zhang J., et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2013, [Epub ahead of print]. 10.1038/leu.2013.279.
21. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421(6925):852-856.
22. Zorn E., Wang K.S., Hochberg E.P., Canning C., Alyea E.P., Soiffer R.J., et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002, 8:2052-2060.
23. MacLennan I.C. Germinal centers. Annu Rev Immunol 1994, 12:117-139.
24. Stevanovic S., Griffioen M., Nijmeijer B.A., van Schie M.L., Stumpf A.N., Rutten C.E., et al. Human allo-reactive C D4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia 2012, 26(2):312-322.
25. Wu C.J., Yang X.F., McLaughlin S., Neuberg D., Canning C., Stein B., et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000, 106:705-714.
26. Kremer A.N., Van Der Griendt J.C., Van Der Meijden E.D., Honders M.W., Ayoglu B., Schwenk J.M., et al. Development of a coordinated allo T-cell and auto B-cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation. Haematologica 2013, [Epub ahead of print].
27. Narita T., Ishida T., Masaki A., Suzuki S., Ito A., Mori F., et al. HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2014, 192:940-947. 10.4049/jimmunol.1301952.
28. Tamai Y., Hasegawa A., Takamori A., Sasada A., Tanosaki R., Choi I., et al. Potential contribution of a novel Tax epitope-specific CD4+ T cells to graft-versus-Tax effect in adult T cell leukemia patients after allogeneic hematopoietic stem cell transplantation. J Immunol 2013, 190:4382-4392.
29. Koyama M., Kuns R.D., Olver S.D., Raffelt N.C., Wilson Y.A., Don A.L., et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med 2012, 18:135-142.
30. Miller J.S., Warren E.H., Van Den Brink M.R., Ritz J., Shlomchik W.D., Murphy W.J., et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant 2010, 16:565-586.
31. Harris A.C., Kitko C.L., Couriel D.R., Braun T.M., Choi S.W., Magenau J., et al. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 2013, 98:179-184.
32. del Campo A.B., Carretero J., Aptsiauri N., Garrido F. Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012, 79:147-154.
33. Stolzel F., Hackmann K., Kuithan F., Mohr B., Fussel M., Oelschlagel U., et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation 2012, 93:744-749.
34. Vago L., Perna S.K., Zanussi M., Mazzi B., Barlassina C., Stanghellini M.T., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488.
35. Wolchok J.D., Weber J.S., Maio M., Neyns B., Harmankaya K., Chin K., et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013, 24:2174-2180.
36. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013, 31:4311-4318.
37. Bashey A., Medina B., Corringham S., Pasek M., Carrier E., Vrooman L., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1581-1588.
38. Koestner W., Hapke M., Herbst J., Klein C., Welte K., Fruehauf J., et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood 2011, 117:1030-1041.
39. Levine J.E., Braun T., Penza S.L., Beatty P., Cornetta K., Martino R., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002, 20:405-412.
40. Schmidt H., Suciu S., Punt C.J., Gore M., Kruit W., Patel P., et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007, 25:1562-1569.
41. Beatty G.L., Smith J.S., Reshef R., Patel K.P., Colligon T.A., Vance B.A., et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res 2009, 15:4944-4953.
42. Porter D.L., Levine B.L., Bunin N., Stadtmauer E.A., Luger S.M., Goldstein S., et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006, 107(4):1325-1331.
43. Buhmann R., Simoes B., Stanglmaier M., Yang T., Faltin M., Bund D., et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3×anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009, 43:383-397.
44. Platzbecker U., Wermke M., Radke J., Oelschlaegel U., Seltmann F., Kiani A., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
45. Schroeder T., Czibere A., Platzbecker U., Bug G., Uharek L., Luft T., et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013, 27:1229-1235.
46. Goodyear O.C., Dennis M., Jilani N.Y., Loke J., Siddique S., Ryan G., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
47. Sergeeva A., Alatrash G., He H., Ruisaard K., Lu S., Wygant J., et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011, 117:4262-4272.
48. Keilholz U., Letsch A., Busse A., Asemissen A.M., Bauer S., Blau I.W., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
49. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
50. Kochenderfer J.N., Dudley M.E., Carpenter R.O., Kassim S.H., Rose J.J., Telford W.G., et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:4129-4139.
51. Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kuhne T., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.
52. Sun Q., Burton R., Reddy V., Lucas K.G. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002, 118:799-808.
53. Haque T., Wilkie G.M., Jones M.M., Higgins C.D., Urquhart G., Wingate P., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
54. Doubrovina E., Oflaz-Sozmen B., Prockop S.E., Kernan N.A., Abramson S., Teruya-Feldstein J., et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119:2644-2656.
55. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360:436-442.
56. Barker J.N., Doubrovina E., Sauter C., Jaroscak J.J., Perales M.A., Doubrovin M., et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010, 116:5045-5049.
57. Leen A.M., Bollard C.M., Mendizabal A.M., Shpall E.J., Szabolcs P., Antin J.H., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.
58. de Lima M., McNiece I., Robinson S.N., Munsell M., Eapen M., Horowitz M., et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012, 367:2305-2315.
59. Chen J., Wang R.X., Chen F., Sun A.N., Qiu H.Y., Jin Z.M., et al. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplant 2013.